The present demonstrated that SSH1 is significantly upregulated in HCC clinical samples, compared to their non-tumor counterpart and this aberrant expression of SSH1 is associated with worse overall and progression-free survival rates. This evidence concerns the gene SSH1 and hepatocellular carcinoma.